Introduction {#sec1}
============

Cancer is a major global public health problem that seriously threatens human health. In recent years, the incidence and mortality of cancer are also increasing year by year. According to GLOBCAN 2012, there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide \[[@B1]\]. In the United States, cancer is the second leading cause of death with an estimated 1,685,210 new cases and 595,690 deaths cancer in 2016 \[[@B2]\]. In China, cancer has been the leading cause of death with an estimated 4,292,000 new cases and 2,814,000 death cases in 2015 \[[@B3]\]. The current strategies to cancer therapy have significantly improved in some types of cancer, such as surgery, radiotherapy or chemotherapy. However, the outcome still remains undesirable. Therefore, looking for effective molecular biomarkers which can be used to evaluate potential risk of cancer is becoming imminent.

With the development of second-generation sequencing technology, more and more long noncoding RNAs (lncRNAs) was been found. LncRNAs were defined as non-protein coding RNAs with the length of more than 200 nucleotides. Recent studies have shown that lncRNAs are closely associated with diverse biological processes, especially in various types of cancer and played an indispensable role in the metastasis and prognosis of cancer \[[@B4]\]. Noteworthily, lncRNAs either could be acted as oncogenes or tumor suppressors in multiple cancers, such as HOPPIP \[[@B5]\] and MEG3 \[[@B6]\]. Urothelial carcinoma associated 1 (UCA1), also known as cancer-resistant drug resistance gene, a 2314-bp lncRNA encoded on human chromosome 19p13.12. UCA1 was a novel lncRNA which was first discovered in 2006 in human bladder cancer and has become a hot spot in recent years \[[@B7],[@B8]\]. Accumulating evidence revealed that UCA1 was dysregulated in cancer tissues and participated in the malignant progression of cancers, including bladder cancer, breast cancer, gastric cancer (GC), colorectal cancer (CRC) and lung cancer \[[@B9]\]. Studies have shown that the dysregulation of UCA1 is closely associated with the clinicopathological characteristics of cancer, such as lymph node metastasis (LNM) and overall survival (OS). However, since the results of the studies were not consistent and small sample size in individual study, we collected relevant publications and performed a meta-analysis to investigate the relationship between UCA1 expression and lymph node metastasis or prognosis, aiming to further evaluate whether the UCA1 could be served as a potential molecular biomarker for cancers.

Materials and methods {#sec2}
=====================

Literature collection {#sec2-1}
---------------------

We searched the electronic databases PubMed, Cochrane Library, Web of science, Embase databases, Chinese National Knowledge Infrastructure (CNKI) and Wanfang, by using 'UCA1 or urothelial carcinoma associated 1' as the keywords, in order to obtain potential articles referenced in the publications. Retrieval time for the last update is up to 17 April 2018.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Inclusion criteria for the articles were as the following: (1) Evaluation of the relationship between UCA1 expression and metastasis, or prognosis of patients in human cancer. (2) Patients were divided into high and low expression group according to the expression levels of UCA1. (3) Related clinicopathologic parameters and outcomes were described, such as LNM and OS. (4) Sufficient data for calculating odds ratio (OR), hazard ratio (HR) and its corresponding 95% confidence intervals (CI).

Exclusion criteria for the articles were as follows: (1) Nonhuman research, reviews, editorials, expert opinions, letters and case reports. (2) Duplicate publications. (3) Studies without valuable data.

Date extraction {#sec2-3}
---------------

Two investigators (H.Y.T. and L.C.M.) extracted and reviewed the essential data from the included studies independently, according to the inclusion and exclusion criteria. Disagreements were solved by two investigators (J.J. and S.J.) by discussions. For each eligible study, we extracted the following information: first author, publication year, tumor type, country, total number of patients, detection method of UCA1, UCA1 expression levels, number of high UCA1 expression group and low UCA1 expression group, number of patients with LNM, follow-up duration, reference control, HRs as well as their 95% CIs.

Quality assessment {#sec2-4}
------------------

The quality of all included studies was assessed by two investigators (W.L.Q. and G.Z.Y.) according to the Newcastle--Ottawa Scale (NOS) independently. For any divergence, a consensus was reached by a third investigator (GTT). NOS scores ranged from 0 to 9 points, with higher scores indicated a better quality and all included eligible studies were assessed to be of high quality by using the NOS in this meta-analysis.

Statistical analysis {#sec2-5}
--------------------

The association between UCA1 and cancer lymph node metastasis or prognosis was assessed by OR and HR with its corresponding 95% CI. The current meta-analysis was performed through Review Manager 5.3 and Stata 12.0 software. We use the χ^2^-based Q test and I^2^ statistics evaluate the heterogeneity of the eligible studies. The random-effects model was used to analyze the results when heterogeneity was present (*I^2^* \> 50%, *P*\<0.05); while the fixed-effects model was applied for this meta-analysis when the heterogeneity was absent in eligible studies (*I^2^* \< 50%, *P*\>0.05). The potential publication bias was assessed with the Begg's funnel-plot. The *P*-value less than 0.05 was considered to be statistically significant.

Results {#sec3}
=======

As shown in [Figure 1](#F1){ref-type="fig"}, a total of 339 published articles were identified from the first attempt to search by using the keywords, of which 145 in English and 194 in Chinese. After removing duplicates, then screening the title and abstract carefully, 248 articles were excluded. After further inspection of the full articles, 53 articles were excluded. Eventually, according to the criteria for selection, a total of 38 studies, of which 1 is in Chinese and the others are in English, were included in the current meta-analysis.

![The flow diagram of the meta-analysis](bsr-39-bsr20180995-g1){#F1}

Literature search and study characteristics {#sec4}
===========================================

[Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} showed the main characteristics of the included researches. A total of 38 studies \[[@B10]\] involving 3411 cancer patients were included. The average patient sample size is 89.76, the maximum sample size is 384, and the minimum sample size is 20. Among the 38 studies, UCA1 was tested in 19 types of cancers, six studies focused on GC, four studies focused on CRC, three studies concentrated on prostate cancer and hepatocellular carcinoma (HCC), respectively; two study on renal cell carcinoma (RCC), ovarian cancer, (OC) pancreatic ductal adenocarcinoma (PDAC) and glioma, respectively, one study on non-small-cell lung cancer (NSCLC), lung cancer, esophageal cancer, esophageal squamous cell carcinoma, gallbladder cancer (GBC), oral squamous cell carcinoma, hypopharyngeal squamous cell carcinoma, urothelial carcinoma (UC), pancreatic cancer, endometrial cancer, breast cancer, osteosarcoma, colon cancer, cholangiocarcinoma (CCA) and multiple myeloma (MM), respectively. All the diagnoses of LNM were based on pathology. In all of the included studies, the patients were divided into two groups: high and low expression of UCA1. All studies used quantitative real-time PCR (qRT-PCR) to detect the expression of UCA1. The main characteristics of the eligible studies were summarized in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### Characteristics of studies about prognosis in this meta-analysis

  Author      Year   Tumor type     Country   Sample size   UCA1 assay   Reference controls   UCA1 expression   Cut-off value   Research type of the studies                                                    
  ----------- ------ -------------- --------- ------------- ------------ -------------------- ----------------- --------------- ------------------------------ ---- ------------------------------------------- ---------------------
  Bian        2016   CRC            China     90            qRT-PCR      β-Actin              45                30              45                             23   Median                                      Case--control study
  Cai Q.      2017   GBC            China     45            qRT-PCR      GAPDH                23                12              22                             18   Median                                      Case--control study
  Chen P.     2016   Pancreatic     China     128           qRT-PCR      GAPDH                64                42              64                             32   Median                                      Case--control study
  Fu          2016   PDAC           China     80            qRT-PCR      GAPDH                40                17              40                             17   Median                                      Case--control study
  Han         2014   CRC            China     80            qRT-PCR      GAPDH                37                17              43                             18   Mean                                        Case--control study
  He          2017   Glioma         China     80            qRT-PCR      β-Actin              51                28              29                             8    NA                                          Case--control study
  Khakiani    2017   GC             Iran      40            qRT-PCR      GUSB                 20                9               20                             5    Median                                      Case--control study
  Li          2014   ESCC           China     90            qRT-PCR      GAPDH                41                22              49                             12   Mean                                        Case--control study
  Li L.       2017   GC             China     102           qRT-PCR      GAPDH                73                44              29                             10   NA                                          Case--control study
  Lu          2016   EC             China     45            qRT-PCR      GAPDH                12                7               33                             5    Median                                      Case--control study
  Ni          2015   CRC            China     54            qRT-PCR      GAPDH                27                12              27                             5    Median                                      Case--control study
  Nie         2016   NSCLC          China     112           qRT-PCR      β-Actin              39                14              73                             21   Youden index                                Case--control study
  Qian        2017   HCC            China     53            qRT-PCR      β-Actin              26                17              27                             9    Median                                      Case--control study
  Tao         2015   CRC            China     80            qRT-PCR      β-Actin              20                13              60                             21   Fourth quartile of the expression of UCA1   Case--control study
  Wang F.     2015   HCC            China     98            qRT-PCR      RNU6B                49                30              49                             11   Median                                      Case--control study
  Wang H.     2015   LC             China     60            qRT-PCR      GAPDH                36                26              24                             8    Median                                      Case--control study
  Wang Z.     2017   GC             China     39            qRT-PCR      GAPDH                22                18              17                             7    Relative expression ratios \<0.5            Case--control study
  Wen         2017   Osteosarcoma   China     151           qRT-PCR      GAPDH                75                44              76                             28   NA                                          Case--control study
  Xu          2017   CCA            China     68            qRT-PCR      GAPDH                38                26              30                             12   NA                                          Case--control study
  Yang Y.J.   2016   OC             China     53            qRT-PCR      GAPDH                27                13              26                             5    Median                                      Case--control study
  Yang Y.T.   2016   OSCC           China     124           qRT-PCR      GAPDH                62                35              62                             20   NA                                          Case--control study
  Zhang L.    2016   OC             China     110           qRT-PCR      GAPDH                57                26              53                             12   Median                                      Case--control study
  Zheng       2015   GC             China     112           qRT-PCR      RNU6B                56                35              56                             37   Median                                      Case--control study
  Zhou        2017   PC             China     72            qRT-PCR      GAPDH                25                9               47                             5    Median                                      Case--control study
  Zuo         2017   GC             China     37            qRT-PCR      RNU6B                18                13              19                             6    Median                                      Case--control study

**Abbreviation**: CCA, cholangiocarcinoma; CRC, colorectal cancer; EC, endometrial cancer; PC, pancreatic carcinoma.

###### Subgroup analysis of the role of UCA1 in LNM in different types of cancer

  Author        Year   Tumor type     Country   Sample size   Detection method   Reference Control   Cut-off value                                      Survival analysis   Multivariate analysis   HR statistic     Hazard ratios (95%)   Follow-up (months)   Research type of the studies
  ------------- ------ -------------- --------- ------------- ------------------ ------------------- -------------------------------------------------- ------------------- ----------------------- ---------------- --------------------- -------------------- ------------------------------
  Bian          2016   CRC            China     90            qRT-PCR            β-Actin             Median                                             OS                  Yes                     Data in paper    2.40 (1.04--5.50)     75                   Case--control study
  Bian          2016   CRC            China     105           qRT-PCR            β-Actin             Median                                             OS                  NO                      Survival curve   1.62 (0.90--2.91)     125                  Case--control study
  Cai Q.        2017   GBC            China     45            qRT-PCR            GAPDH               Median                                             OS                  NO                      Survival curve   2.08 (1.01--4.29)     40                   Case--control study
  Chen D.       2015   PDAC           U.S.A.    63            qRT-PCR            NA                  Median                                             OS                  NO                      Survival curve   2.76 (1.15--6.61)     21                   Case--control study
  Chen P.       2016   Pancreatic     China     128           qRT-PCR            GAPDH               Median                                             OS                  Yes                     Data in paper    1.50 (1.01--2.24)     60                   Case--control study
  Fu            2015   PDAC           China     80            qRT-PCR            GAPDH               Median                                             OS                  Yes                     Data in paper    2.02 (1.02--4.01)     40                   Case--control study
  Gao           2015   GC             China     20            qRT-PCR            GAPDH               NA                                                 OS                  Yes                     Data in paper    2.02 (1.02--3.37)     40                   Case--control study
  Han           2014   CRC            China     80            qRT-PCR            GAPDH               Mean                                               OS                  NO                      Survival curve   7.44 (1.84--30.15)    42.6                 Case--control study
  He            2017   Glioma         China     80            qRT-PCR            β-Actin             NA                                                 OS                  NO                      Survival curve   1.52 (0.61--3.78)     35                   Case--control study
  Jiao          2016   Esophageal     China     66            qRT-PCR            NA                  Median                                             OS                  NO                      Survival curve   3.36 (1.48--7.61)     30                   Case--control study
  Johanna       2017   UC             Germany   106           qRT-PCR            SDHA/TBP            Median                                             OS                  Yes                     Data in paper    0.57 (0.37--0.90)     200                  Case--control study
  Khakiani      2017   GC             Iran      40            qRT-PCR            GUSB                Median                                             OS                  NO                      Survival curve   4.08 (1.63--10.22)    100                  Case--control study
  Li            2014   ESCC           China     90            qRT-PCR            GAPDH               Mean                                               OS                  Yes                     Data in paper    2.63 (1.42--5.87)     60                   Case--control study
  Liu           2016   BC             China     54            qRT-PCR            GAPDH               Median                                             OS                  NO                      Survival curve   2.08 (1.04--4.15)     60                   Case--control study
  Lu            2016   EC             China     45            qRT-PCR            GAPDH               Median                                             OS                  NO                      Survival curve   3.95 (1.20--12.96)    60                   Case--control study
  Lu Y.         2017   RCC            China     50            qRT-PCR            GAPDH               Median                                             OS                  NO                      Survival curve   3.20 (1.41--7.26)     60                   Case--control study
  Na            2015   PC             China     40            qRT-PCR            GAPDH               Median                                             OS                  Yes                     Survival curve   1.52 (1.23--1.88)     60                   Case--control study
  Ni            2015   CRC            China     54            qRT-PCR            GAPDH               Median                                             OS                  NO                      Survival curve   3.14 (1.17--8.41)     50                   Case--control study
  Nie           2016   NSCLC          China     112           qRT-PCR            β-Actin             Youden index                                       OS                  Yes                     Data in paper    1.41 (1.08--1.84)     60                   Case--control study
  Qian          2017   HSCC           China     53            qRT-PCR            β-Actin             Median                                             OS                  NO                      Survival curve   1.83 (0.89--3.78)     60                   Case--control study
  Sedlarikova   2017   MM             Czech     64            qRT-PCR            RPLP0               NA                                                 OS                  Yes                     Data in paper    1.94 (1.17--3.22)     60                   Case--control study
  Tao           2015   CC             China     80            qRT-PCR            β-Actin             Fourth quartile of the expression level of UCA1.   OS                  Yes                     Data in paper    2.00 (1.01--3.98)     60                   Case--control study
  Wang F.       2015   HCC            China     98            qRT-PCR            RNU6B               Median                                             OS                  Yes                     Data in paper    1.86 (1.08--3.21)     60                   Case--control study
  Wang H.       2015   LC             China     60            qRT-PCR            GAPDH               Median                                             OS                  Yes                     Data in paper    1.94 (1.06--3.26)     60                   Case--control study
  Wang Y.       2017   RCC            China     384           qRT-PCR            NA                  NA                                                 OS                  Yes                     Data in paper    1.92 (1.36--2.70)     150                  Case--control study
  Wen           2017   Osteosarcoma   China     151           qRT-PCR            GAPDH               NA                                                 OS                  Yes                     Data in paper    2.52 (1.35--4.83)     60                   Case--control study
  Xu            2017   CCA            China     68            qRT-PCR            GAPDH               NA                                                 OS                  Yes                     Data in paper    2.27 (1.31--3.94)     60                   Case--control study
  Yang Y.J.     2016   OC             China     53            qRT-PCR            GAPDH               Median                                             OS                  Yes                     Data in paper    6.32 (1.12--35.68)    50                   Case--control study
  Yang Z.       2015   HCC            Korea     240           qRT-PCR            NA                  Median                                             OS                  Yes                     Data in paper    1.99 (0.84--4.69)     120                  Case--control study
  Zhang L.      2016   OC             China     110           qRT-PCR            GAPDH               Median                                             OS                  Yes                     Data in paper    1.69 (1.01--2.83)     60                   Case--control study
  Zhang S.      2017   PC             China     47            qRT-PCR            GAPDH               NA                                                 OS                  NO                      Survival curve   2.09 (0.80--5.46)     60                   Case--control study
  Zhao          2017   Glioma         China     64            qRT-PCR            GAPDH               \>22.20                                            OS                  NO                      Data in paper    7.37 (3.03--17.90)    48                   Case--control study
  Zheng         2015   GC             China     112           qRT-PCR            RNU6B               Median                                             OS                  Yes                     Data in paper    2.35 (1.22--4.52)     60                   Case--control study
  Zheng Z.      2018   HCC            China     105           qRT-PCR            GAPDH               Median                                             OS                  Yes                     Data in paper    3.65 (1.17--4.65)     60                   Case--control study
  Zhou          2017   PC             China     72            qRT-PCR            GAPDH               Median                                             OS                  NO                      Survival curve   1.87 (0.54--6.53)     60                   Case--control study
  Zuo           2017   GC             China     37            qRT-PCR            RNU6B               Median                                             OS                  Yes                     Data in paper    2.92 (1.07--7.96)     40                   Case--control study

**Abbreviation**: CCA, cholangiocarcinoma; CRC, colorectal cancer; EC, endometrial cancer; PC, pancreatic carcinoma.

Meta-analysis results {#sec5}
=====================

Association between UCA1 and LNM {#sec5-1}
--------------------------------

The 25 studies ([Table 1](#T1){ref-type="table"}) reported a total of 2003 patients with LNM based on different UCA1 expression levels. The random-effects model was adopted as the moderate heterogeneity (*I^2^*= 43%, *P*=0.01). Analysis showed that the OR of high UCA1 expression group versus low UCA1 expression group was 2.50 (95% CI: 1.93--3.25; *P*\<0.00001) ([Figure 2](#F2){ref-type="fig"}), which revealed that a higher UCA1 expression predicted more LNM. The result indicated that patients with high UCA1 expression in cancer tissues were more susceptible to LNM.

![Forest plot for the association between UCA1 expression levels with LNM](bsr-39-bsr20180995-g2){#F2}

Association between UCA1 and OS {#sec5-2}
-------------------------------

A total of 36 studies including 3146 patients were assessed for the correlation between UCA1 and OS ([Table 2](#T2){ref-type="table"}), High UCA1 expression was significantly correlated with poor prognosis, compared with low UCA1 expression in a pooled analysis of all studies (HR = 2.05; 95% CI: 1.77--2.38; *P*\<0.00001) ([Figure 3](#F3){ref-type="fig"}). The random-effects model was used because of the moderate heterogeneity (*I^2^* = 48%, *P*=0.0008). In other words, high UCA1 expression group shortened the OS compared with low UCA1 expression group.

![Forest plot for the association between UCA1 expression levels with OS](bsr-39-bsr20180995-g3){#F3}

Subgroup analysis {#sec5-3}
-----------------

Subgroup analyses across several different variables were further performed to investigate the heterogeneity of the studies for meta-analysis of UCA1 and LNM or OS. The LNM-related data were stratified into subgroups based on sample size, tumor type, cut-off value and reference control. The assessment results in each subgroup are also shown in [Table 3](#T3){ref-type="table"}. Subgroup analysis by sample size explored that high UCA1 expression status was related to high LNM numbers both in big (*n*≥100, OR = 1.99, 95% CI: 1.50--2.65, *P*\<0.0001) and small sample size group (*n*\<100, OR = 2.71, 95% CI: 2.12--3.47, *P*\<0.00001). And we also found a significantly positive correlation between UCA1 expression and LNM when grouped by different cut-off value \[By median (OR = 2.48, 95% CI: 1.63--3.78, *P*\<0.0001) and By others (OR = 2.53, 95% CI: 1.92--3.34, *P*\<0.00001)\]. However, when conducting subgroup analyses on tumor type, we found no significant correlation between high UCA1 expression and LNM among the studies in respiratory system (OR = 2.54, 95% CI: 0.70--9.23, *P*=0.16). According to the results presented in [Table 3](#T3){ref-type="table"}, when divided by reference control, the subgroup analysis showed that up-regulated UCA1 was associated with more LNM in GAPDH group (OR = 2.41, 95% CI: 1.91--3.04, *P*\<0.00001) and β-actin group (OR = 2.35, 95% CI: 1.54--3.57, *P*\<0.0001), while no significant association in RNU6B/GUSB group (OR = 2.69, 95% CI: 0.95--7.56, *P*=0.06).

###### Subgroup analysis of the role of UCA1 in LNM in different types of cancer

  Subgroup analysis     No. of studies   No. of patients   Test of relationship   Test of heterogeneity        
  --------------------- ---------------- ----------------- ---------------------- ----------------------- ---- -------
  Overall               25               2003              2.50 (1.93--3.25)      \<0.00001               43   0.01
  Sample size                                                                                                  
  \<100                 18               1164              2.71 (2.12--3.47)      \<0.00001               46   0.02
  ≥100                  7                839               1.99 (1.50--2.65)      \<0.00001               23   0.25
  Tumor type                                                                                                   
  Respiratory system    2                172               2.54 (0.70--9.23)      0.16                    71   0.06
  Digestive system      17               1320              2.27 (1.61--3.20)      \<0.00001               52   0.006
  Reproductive system   3                208               3.65 (1.96--6.81)      \<0.0001                0    0.51
  Others                3                303               2.90 (1.77--4.77)      \<0.0001                0    0.63
  Cut off                                                                                                      
  Median                15               1077              2.48 (1.63--3.78)      \<0.0001                59   0.002
  Others                10               926               2.53 (1.92--3.34)      \<0.00001               0    0.54
  Reference control                                                                                            
  GAPDH                 16               1301              2.41 (1.91--3.04)      \<0.00001               45   0.03
  β-Actin               5                415               2.35 (1.54--3.57)      \<0.0001                0    0.5
  RNU6B/GUSB            4                287               2.69 (0.95--7.56)      0.06                    74   0.009

The OS-related data were stratified into subgroups based on sample size, tumor type, cut-off value, follow-up time, analysis method, race and reference control. The detailed assessment results in each subgroup are also shown in [Table 4](#T4){ref-type="table"}. Subgroup analysis by sample size, cut-off value, follow-up time, analysis method and reference control all revealed that high UCA1 expression was significantly associated with poor OS in each groups. However, when conducting subgroup analyses on tumor type, we found high UCA1 expression was remarkably related to poor OS among respiratory system, digestive system, reproductive system and other systems but no significant correlation between high UCA1 expression and OS among the studies in urinary system (HR = 1.54, 95% CI: 0.98--2.40, *P*=0.06). As for different race for UCA1, the relationship between UCA1 expression and OS was significant in Asian group (HR = 1.90, 95% CI: 1.72--2.10, *P*\<0.00001), but not in others group (HR = 1.39, 95% CI: 0.52--3.71, *P* = 0.51).

###### Subgroup analysis of the role of UCA1 in OS in different types of cancer

  Subgroup analysis            No. of studies   No. of patients   Test of relationship   Test of heterogeneity        
  ---------------------------- ---------------- ----------------- ---------------------- ----------------------- ---- --------
  Overall                      36               3146              2.05 (1.77--2.38)      \<0.00001               48   0.0008
  Sample size                                                                                                         
  \<100                        26               1593              2.03 (1.80--2.30)      \<0.00001               14   0.26
  ≥100                         10               1553              1.67 (1.25--2.22)      0.0005                  71   0.0003
  Tumor type                                                                                                          
  Respiratory system           2                172               1.50 (1.17--1.91)      0.001                   0    0.32
  Digestive system             20               1654              2.18 (1.87--2.55)      \<0.00001               0    0.76
  Urinary system               6                699               1.54 (0.98--2.40)      0.06                    78   0.0003
  Reproductive system          3                208               2.10 (1.32--3.33)      0.002                   39   0.19
  others system                5                413               2.37 (1.75--3.22)      \<0.00001               49   0.10
  Region                                                                                                              
  Asian                        33               2913              1.90 (1.72--2.10)      \<0.00001               21   0.14
  Non Asian                    3                233               1.39 (0.52--3.71)      0.51                    88   0.0002
  Cut off                                                                                                             
  Median                       24               1906              2.01 (1.65--2.45)      \<0.00001               51   0.0002
  Others                       12               1240              1.92 (1.65--2.24)      \<0.00001               43   0.06
  Analysis method                                                                                                     
  Non-multivariable analysis   15               918               2.55 (2.04--3.18)      \<0.00001               9    0.35
  Multivariable analysis       21               2228              1.83 (1.55--2.16)      \<0.00001               51   0.004
  Reference control                                                                                                   
  GAPDH                        19               1416              1.96 (1.72--2.22)      \<0.00001               35   0.06
  β-actin                      6                520               1.57 (1.27--1.93)      \<0.0001                0    0.81
  Other controls               10               1210              2.00 (1.37--2.93)      0.0004                  72   0.0002
  Follow-up (months)                                                                                                  
  \<60                         11               642               2.71 (2.09--3.51)      \<0.00001               14   0.31
  ≥60                          25               2504              1.71 (1.54--1.89)      \<0.00001               47   0.005

Sensitivity analysis {#sec5-4}
--------------------

Multiple sensitivity analyses were carried out to evaluate whether individual study influenced pooled ORs or HRs by excluding one study by turns. It was found that none of the exclusions of a specific study would change the magnitude or direction of the summary effect for the correlation between UCA1 expression and LNM or OS, which further confirmed the validity of the results ([Figures 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}).

![Sensitivity analysis for the association between UCA1 expression levels with LNM](bsr-39-bsr20180995-g4){#F4}

![Sensitivity analysis for the association between UCA1 expression levels with OS](bsr-39-bsr20180995-g5){#F5}

Publication bias {#sec5-5}
----------------

Egger's test and funnel plot were introduced to evaluate potential publication bias in our present meta-analysis. No evidence supporting publication bias was found in analysis between UCA1 and LNM (Egger's test, *t* = 1.31, *P*=0.202) ([Figure 6](#F6){ref-type="fig"}). However, the shapes of funnel plot were asymmetric and Egger's test displayed slightly publication bias for the HR evaluation of OS (Egger's test, *t* = 4.76, *P*\<0.05) ([Figure 7](#F7){ref-type="fig"}). Because of this, trim and fill was used to perform a sensitivity analysis. This method conservatively conjectures hypothetical negative unpublished studies to reflect positive studies that lead to funnel plot asymmetry, and then a symmetrical funnel plot appears ([Figure 8](#F8){ref-type="fig"}). While the statistically significant relationship between UCA1 expression and OS was also shown in pooled analysis incorporating the hypothetical studies, indicating that the result was stable and publication did not have an impact on it though publication bias exists.

![Funnel plot analysis of potential publication bias for LNM](bsr-39-bsr20180995-g6){#F6}

![Funnel plot analysis of potential publication bias for OS](bsr-39-bsr20180995-g7){#F7}

![Funnel plot analysis of potential publication bias for OS with trim and fill](bsr-39-bsr20180995-g8){#F8}

Discussion {#sec6}
==========

Evidence from multiple publications demonstrated that lncRNAs, similar to protein-coding genes, can act as oncogenes or tumor suppressor genes, which involving in a variety of tumorigenesis processes, including proliferation, invasion, migration and apoptosis. With the rapid development of high-throughput genome-wide analysis technology, more and more functional lncRNAs have been found to have potential value on predicting cancer progression. UCA1, a novel functional lncRNA which was first discovered in 2006 in human bladder cancer. In recent years, a growing number of studies have shown that UCA1 up-regulated in several cancers, including HCC, GC and lung cancer \[[@B7]\]. UCA1 involved in tumor proliferation, invasion, migration and apoptosis, and played an important role in tumor progression, metastasis and prognosis. However, a persuasive support of the UCA1 in clinical practice is still controversial, partially due to the uncertainty of the relationship between UCA1 and metastasis or prognosis implication. Several literatures established a statistically significant relationship between high UCA1 expression and lymph node metastasis or prognosis. Nevertheless, some studies showed no statistical impact of UCA1 dysregulation on cancer metastasis and prognosis. In order to combine previous research results about UCA1 and cancers to arrive at a summary conclusion, a comprehensive study is performed.

In the present meta-analysis, we systematically explore the relationship between UCA1 and cancer metastasis or prognosis. The results of the current study demonstrated that high UCA1 expression level was positively related to increasing the risk of LNM in cancer patients. Moreover, we also identified that there was a significantly positive correlation between high UCA1 expression and short OS in cancer patients. In multiple sensitivity analyses, we did not detect any substantial difference in pooled estimates, and there was no excessive influence on the overall results in any individual study.

The exact mechanisms underlying the association between elevated UCA1 expression and more LNM or poor prognosis is poorly understood, and the related reports are not the same, but many similarities were still existed. Several literatures have suggested potential mechanisms that could be involved in the metastasis and prognostic impact of UCA1 on carcinogenesis. First, UCA1 could act as a key competing endogenous RNA (ceRNA) or sponge for *miR-204-5p, miR-193a-3p, miR-145, miR-143, miR-216b, miR-203, miR-196a-5p* and *miR-135a* in several different cancers. For example, Zhang et al. found that UCA1 could directly interacted with *miR-204* and functioned as a ceRNA, thus regulating the expression of ATF2 and promoting cell proliferation and metastasis in prostate cancer \[[@B16]\]. Nie et al. found UCA1 up-regulated the expression level of *miR-193a-3p* target gene ERBB4 by competitively 'spongeing' *miR-193a-3p* in NSCLC \[[@B26]\]. In bladder cancer, Xue et al. demonstrated that UCA1 induced epithelial--mesenchymal transition (EMT) of bladder cancer cells through up-regulating the expression of zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2), and also regulated cell migration and invasion of bladder cancer by suppressing *miR-145* and its target gene the actin-binding protein fascin homologue 1 (FSCN1) \[[@B48]\]. In HCC, Wang et al. found UCA1 acted as an endogenous sponge through binding to *miR-216b* directly and down-regulated the expression of *miR-216b*. UCA1 reversed the inhibitory effect on the growth and metastasis of *miR-216b* of HCC, which might be involved in the suppression of fibroblast growth factor receptor 1 (FGFR1) expression, a target gene of *miR-216b*, and the activation of ERK signaling pathway \[[@B42]\]. In addition, Xiao et al. showed that UCA1 up-regulation promoted cell EMT in HCC via sponging to *miR-203* effectively and thus activating the expression of transcription factor Snail2 and promote HCC progression \[[@B49]\]. In bladder cancer, UCA1 could promote glycolysis by up-regulating hexokinase 2 through both activation of STAT3 and repression of *miR-143* \[[@B50]\]. UCA1-activated transcription factor CREB which resulting in *miR-196a-5p* expression by binding with its promoter and thereby modulating the influence on cisplatin/gemcitabine resistance \[[@B51]\]. Second, UCA1 promoted the progression of different cancer by activating of the Wnt/β-catenin signaling pathway. UCA1 down-regulation increased the tamoxifen sensitivity through inhibiting Wnt/β-catenin pathway in breast cancer cells while UCA1 up-regulation promoted EMT of breast cancer cells by activating Wnt/β-Catenin signaling pathway \[[@B31],[@B52]\]. Silence UCA1 suppressed cell proliferation and metastasis and induced cell apoptosis of oral squamous cell carcinoma, which might be significantly correlated with the activation level of the Wnt/β-Catenin signaling pathway \[[@B11]\]. Fan et al. indicated that UCA1 could increase the cisplatin resistance of bladder cancer cells by regulating the Wnt signaling \[[@B53]\]. Third, UCA1 overexpression could promote cancer metastasis by activation of metastasis-related genes including GRK2/ERK-MMP9, EZH2/AKT, p21/E-cadherin, iASPP, KLF4-KRT6/13, FGFR1/ERK and ZEB1/2-FSCN1. UCA1 overexpression could increase the metastatic ability of GC cells through regulating GRK2 protein stability by promoting Cbl-c-mediated GRK2 ubiquitination and degradation, thus activate the ERK-MMP9 signaling pathway \[[@B54]\]. Mechanically, UCA1 promoted the cell proliferation and metastasis of GBC by recruiting enhancer of zeste homolog 2 (EZH2) to the promoter of p21 and E-cadherin, and epigenetically suppressing their transcript \[[@B43]\]. He et al. demonstrated that UCA1 overexpression promoted cell proliferation and migration of glioma, to regulate the tumor growth and metastasis via *miR-182* dependent iASPP regulation \[[@B35]\]. Wang et al. suggested that UCA1 overexpression contributed to the growth and metastasis of HCC via inhibiting *miR-216b* and activating FGFR1/ERK signaling pathway \[[@B42]\]. Simultaneously, UCA1 also remarkably associated with prognosis of patients with different cancer and may be a potential diagnosis biomarker in hepatocellular cancer, CRC and GC.

Otherwise, some limitations to this meta-analysis should be taken into account. First, the cut-off values of UCA1 high and low expression were lack of uniform standard due to different methods and criteria in different types of cancer, which may result in some heterogeneity and affect the results of the study. Second, most studies tended to report positive results rather than negative results; our meta-analysis may overestimate the significance of UCA1 to some extent. Third, some of the HRs were estimated from survival curves rather than directly obtained from the primary studies. Lastly, most of the included studies were performed in the population from Asian countries rather than worldwide population; our results should be substantiated by additional studies in other races. Although there are some limitations, but this current meta-analysis still has its noteworthy advantages. First, 38 literatures which including a total of 3411 cases and 19 types of cancer were included in this meta-analysis. The sample size included was the largest, which significantly improved the statistical efficiency and accuracy of the test. Second, the number of search databases were greater and cancer types were more comprehensive in this meta-analysis compared with previous reports. Finally, the inclusion and exclusion criteria were more stringent and the quality of the literatures incorporated was higher.

Conclusion {#sec7}
==========

In conclusion, even some limitations mentioned above, our meta-analysis reveals that the expression level of UCA1 was significantly associated with metastasis and prognosis in different types of cancer. The higher expression of UCA1, the higher probability of occurrence of LNM cancer patients suffer with. Meanwhile, shorter OS may be observed in the patients with high UCA1 expression. Thus, UCA1 might be a novel predictive marker for estimating the metastasis and prognosis in different types of cancer. However, the significance of UCA1 in LNM in respiratory system cancers and RNU6B/GUSB reference control group should incorporate more studies to validate this result, and so does in urinary system prognosis and non-Asian people prognosis.
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:   competing endogenous RNA
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:   colorectal cancer
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EC

:   endometrial cancer
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HCC
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:   multiple myeloma
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qRT-PCR

:   quantitative real-time PCR
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:   phospho-signal transducer and transcription activator 3
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